Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) pre-open: “What light through yonder window breaks?"

August 23, 2018 8:32am

I ask having thought we would have a continued upside trend, “don't swear by the moon” the sector replied …

Pre-market indications: BUY on news (3), OVERBOUGHT (5) and a BUY (1)

I follow the dictum, quoting Churchill that “short words are best and the old words when short are best of all.”

Spare the SELL call, underfund the portfolio – SUBSCRIBE!

U.S. stock index futures are flattened

Dow futures are UP +0.04% (+11 points) and NASDAQ futures are DOWN -0.03% (-3 points)

U.S. stock index futures traded flat Thursday, as the U.S. and China hit one another with a new round of tariffs.

Europe stocks hovered around the flat line

Asian markets were mixed with mainland China markets closing higher despite US tariffs kicking in

Data docket: weekly jobless claims figures are due at 8:30 a.m. ET, while flash Composite Purchasing Managers' Index (PMI) data are due at 9:45 a.m. ET.

Today’s indications:

The iShares Nasdaq Biotechnology (IBB) is NOT indicating in Thursday’s pre-market;
The SPDR S&P Biotech ETF (XBI) is NOT indicating in Thursday’s pre-market;
The Health Care Select Sector SPDR ETF (XLV) is NOT indicating in Thursday’s pre-open;
The iShares Russell 2000 (IWM) is indicating a -0.24% DOWNSIDE in Thursday’s pre-open

Henry’omics:

Domestic political news also weighed on sentiment although the current U.S. bull market has found its way into the history books, becoming the largest on record, spanning 3,453 days.

I’d be watching my positions today – not to SELL into a drift buy, but strength either way to play!

I always want to know what happened PRIOR to what might happen today – it sets a tone of consequence:

From Wednesday’s night’s newsletter: “hop, skip and a few slips. Gene editing firms, CRSP and NTLA felt the sharp end of the stick while EDIT was barely positive. Another told you so …!”

I also stated, “There is going to be a sector sell-off based on trading seeking to capitalize on many of the “ups” ... but a present it is a nonevent but, by Friday …?”

The iShares NASDAQ Biotechnology (IBB): Wednesday closed at +0.71% after Tuesday’s +0.93%, Monday’s -0.17%, Friday’s +0.02 % and last Thursday’s +0.77% for a five session aggregate of +2.26% - looking foe some downside!

Of the 45 companies covered on Wednesday; 12 downside equities finished in a range of -0.08% (QURE) to -5.14% (CRSP) while the 32 upside equities oscillated from +0.07% (RGNX) to +7.71% (MDXG) with 1 flat close (SGMO).

August’s measurement:

Of the past 5 sessions – 5 had closed positive,
Of the past 10 sessions – 3 had closed negative
Of the 15 August sessions – 5 had negative and 11 positive closes

Companies in my headlights – It’s your decision; I provide the idea and context:

…. Everyone deserves a vacation – I keep trying!

BUY on news:

Global Blood Technologies (GBT)

bluebird bio (BLUE)

uniQure (QURE)

Overbought:

Applied Genetic Technologies (AGTC)

BioLife Solutions (BLFS),

Editas Medicine (EDIT),

Intellia Therapeutics (NTLA),

Verastem Oncology (VSTM)

CRISPR Therapeutics (CRSP) – SELL to BUY

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.